Multiple Myeloma Market Size

Multiple Myeloma Market size was over USD 28.89 billion in 2024 and is poised to reach USD 178.71 billion by the end of 2037, growing at around 14.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of multiple myeloma is assessed at USD 32.36 billion. Multiple myeloma is a rare type of cancer, which is increasing nowadays. The market is growing on account of growing awareness among people related to disease symptoms.

In addition, the number of diagnoses is increasing. The manufacturers are designing and developing new products and drugs for the treatment of multiple myeloma. These factors are bolstering the market growth of multiple myeloma market. Also, the advancement in therapies and drugs is growing owing to the reports indicating an increase in the incidence of multiple myeloma around the world. According to data from 2015 to 2019, 7.1 persons will receive a myeloma diagnosis per 100,000 people each year. It will cause about 3.2 out of 100,000 deaths.

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of multiple myeloma is assessed at USD 32.36 billion.

The multiple myeloma market size was over USD 28.89 billion in 2024 and is poised to reach USD 178.71 billion by the end of 2037, growing at around 14.8% CAGR during the forecast period i.e., between 2025-2037. Growing incidences of multiple myeloma, growing number of product unveilings and increase in the initiatives taken by the government will drive the market growth.

North America industry is holding the largest share of about 33% by 2037, owing to increasing demand for the treatment and implementation of advanced therapeutics in the region.

The major players in the market include Bristol-Myers Squibb Company, Amgen Inc., Johnson & Johnson, Novartis AG, Sanofi, Janssen Pharmaceuticals Inc., Genentech, Inc., AbbVie Inc., Karyopharm.

Multiple Myeloma Market Size